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Spontaneous reports (SRs) of suspected adverse events associated with 
biopharmaceuticals and other medical products are key sources for identifying 
potential new drug hazards. They are required by most regulatory agencies as 
well as large drug distribution projects, e.g., HIV/TB programs. The WHO collects 
these pharmacovigilance data from >100 countries. Many databases conform to 
WHO’s Council for International Organizations of Medical Sciences (CIOMS) 
standard data fields. B.R.I.D.G.E. TO DATA (www.bridgetodata.org), an 
international resource of database profiles, can serve as a template and 
complement the CIOMS effort. OBJECTIVES: Analyze SR database profiles and 
classify use of data fields. METHODS: We identified databases profiled in 
B.R.I.D.G.E. collecting SR data using two search criteria: Database 
Type=Spontaneous reporting systems; and Database Source=Spontaneous reports. 
Twenty of 198 profiles matched ≥1 criteria; frequency of use of the 75 data fields 
were compared. Based on use frequency, fields were categorized into Group 1 (G1 
- consensus in use of field among the set), Group 2 (G2 - use by ≥50% databases), 
or Group 3 (G3 - use by <50% databases). RESULTS: Of the 75 data fields, 53 (71%) 
were frequently used among databases with SR data: 21 (28%) were classified 
into G1 (e.g., Diagnosis data, Drug data), and 32 (43%) into G2 (e.g., Death 
recorded, Physician specialty). Fields utilized less frequently (n=22; 29%) 
comprised G3 (e.g., Medical Record Access, Linkage Capabilities). Analysis of G1 
revealed that a majority of SR databases are funded by government agencies, 
capture OTC & prescription drug use in inpatient & outpatient settings; however, 
diagnosis data are heterogeneously coded. Of the 25 fields on the CIOMS 
reporting form, 17 corresponded to G1, and 8 to G2. CONCLUSIONS: In this 
analysis, B.R.I.D.G.E. served as a screening tool to categorize data fields used in 
SR databases and successfully identified additional fields to complement the 
CIOMS effort.  
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WHAT IS THE OPTIMAL SEARCH ENGINE FOR RESULTS FROM EMBASE AND 
MEDLINE: OVID OR EMBASE.COM?  
Fortier KJ, Kiss N, Tongbram V 
Oxford Outcomes, Morristown, NJ, USA  
OBJECTIVES: Ovid and Embase.com are two search engines that are commonly 
used for searching the Medline and Embase databases. The standard of practice 
for conducting a search for a systematic literature review seems to support the 
use of Ovid. Our objective was to discern the advantages and disadvantages of 
both the Embase.com and Ovid search engines. We sought to compare the two 
databases in the following ways: results of a search, and ease of searching. 
METHODS: We conducted several searches to see if there were any differences in 
results. We analyzed the variation in results to determine why the disparities 
existed. We wrote a step-by-step search guide and highlighted the 
differences/difficulties encountered. Using a set of written directions, we also 
asked researchers to conduct searches using both interfaces and rate ease of use 
on a scale of 0 through 5. Research was also conducted through websites and 
help desks to ascertain the disparities in content between the two search 
engines. RESULTS: There were differences in the search results between Ovid 
and Embase.com using the same search criteria. The coding of articles 
sometimes differed, but there were very few, if any, relevant articles that were 
missed by either engine. In terms of ease of use, Embase.com had lower scores 
indicating greater ease of use in searching, exporting into a reference manager, 
saving searches, and recalling data compared to Ovid. In the research assessing 
the differences in content through the company websites, we found that 
Embase.com alleged to contain articles published further in the past, include 
more conference abstracts, and update Emtree terms more frequently than did 
Ovid. CONCLUSIONS: There is no notable difference between Ovid and 
Embase.com in terms of search results when searching Embase and Medline. 
However, Embase.com was rated as easier to use in several domains compared 
to Ovid.  
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STATE-LEVEL, POPULATION-BASED CANCER REGISTRY AND ADMINISTRATIVE 
DATA LINKAGES IN THE UNITED STATES: A REVIEW OF THE LITERATURE  
Foley K1, Miller J1, Bradley CJ2 
1Truven Health Analytics, Cambridge, MA, USA, 2Virginia Commonwealth University, Richmond, 
VA, USA  
OBJECTIVES: Observational studies using administrative claims data are 
increasingly used for oncology outcomes research. The only population-based 
administrative data inclusive of disease stage and death from registries, 
however, are the SEER-Medicare data which exclude the under 65 population. 
Many state cancer registry and claims data linkages exist, but little is known 
about them. We conducted a literature review to identify and describe U.S. state-
level, population-based cancer data linkages. METHODS: PubMed was searched 
for all years using the keywords “registry,” “cancer OR oncology,” and “claims OR 
administrative.” Inclusion criteria were U.S. state cancer registries and 
administrative claims data linkages, exclusive of the SEER-Medicare database. 
RESULTS: A total of 687 abstracts were identified; 74 articles met the inclusion 
criteria. These papers represented 21 state cancer registries and linkages to 
Medicaid, Medicare, commercial insurance claims, state-level hospital discharge 
files, state-level screening program data, or state health care agency 
administrative files. Most linked Medicaid (N=12) and Medicare (N=9) data to 
assess quality of cancer care for specific types of cancer. Eighty percent of states 
specifically linked data on breast-cancer, 40% linked colorectal cancer, 25% 
linked on cervical, prostate or lung, and 40% were inclusive of all cancers. Only 
seven states (35%) linked commercial claims data or hospital discharge data 
(representing the under 65 population). CONCLUSIONS: Significant work is being 
conducted at the state level to generate cancer data, yet the under 65 population 
remains under-represented among linked cancer lives. Although fragmented, the 
existing linkages provide a foundation on which to build a more comprehensive 
oncology data system. Maintaining and expanding these data are critical for 
quality assessments, and disparity, outcomes and comparative effectiveness 
research. Barriers related to proprietary data and sustainable funding for 
linkages must be addressed before a data infrastructure that is broadly 
representative of the US national population can be generated.  
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IDENTIFYING CHRONIC KIDNEY DISEASE STAGES USING PATIENT 
PRESCRIPTION INFORMATION  
Cai Y1, Han Y2, Jiao X3, Mu G1 
1IMS Health, Plymouth Meeting, PA, USA, 2IPSEN Biopharmaceuticals, Inc., Basking Ridge, NJ, 
USA, 3IMS Health, Alexandria, VA, USA  
OBJECTIVES: It’s important for health care policy makers, payers and drug 
manufacturers to identify Chronic Kidney Disease (CDK) patient stages in order 
to evaluate the prevalence, economic burden or market opportunities. The office 
based medical claims data, which contains ICD-9 diagnosis and treatment 
information of CDK stages, has very limited coverage. To identify more CDK 
patients, we built and compared varies of statistical models and machine 
learning algorithms to project CKD stages using prescription database. 
METHODS: The model data contained year 2011 patient level CKD stage 
indications, longitudinal drug therapies, days of supplies, titration rates, 
Demographic characteristics, payment type, and physician specialties, etc. The 
data were randomly divided into a training set (66.7%) and a validation set 
(33.3%). The classification models used were Logistic regression, linear/quadratic 
Discriminant, Classification and Regression Tree (CART), C4.5 decision tree, Logit 
Boost classification tree, Bayes learning networks, Support Vector Machine and 
Neural networks. Bagging and boosting techniques were also tested to improve 
the precision. RESULTS: Logistic regression showed the best classification 
accuracy out of all models. The overall correct classification rate was 66.8%, 
Kappa Statistics 0.35, F-measure 0.63 and receiver operating characteristic  
(ROC) area 0.75. Among all CDK stages, CDK stage 1-3 were predicted most 
accurately with True Positive Rate (TPR) 93% and 65% precision. ESRD  
was moderately identified with TPR 46% and precision 76%. CDK 4 was most 
difficult to identify, with TPR 9% and precision 40%. The bagging and boosting 
improved decision trees showed comparable results. CONCLUSIONS: The 
modern machine learning algorithms were proved to be more accurate in many 
cases but for the CKD dataset the classical logistic model worked out better. The 
logistic model could fairly classify severe CKD stages (4-5) patients from lower 
stages (1-3) using prescription information but it had hard time to separate CKD 
stage 4 from 5.  
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THE IMPACT OF CIGARETTE SMOKING ON MORTALITY FOR DIABETIC 
PATIENTS: A PROPENSITY SCORE MATCHING APPROACH  
Cai B, McAdam Marx C, Nelson RE 
University of Utah, Salt Lake City, UT, USA  
OBJECTIVES: Confounding issues have not been accommodated adequately in 
the public health literature of smoking. This study examines the impact of 
smoking on mortality for patients with diabetes using a propensity score 
matching approach. METHODS: We employed the National Health Interview 
Survey (NHIS) data from 1997 to 2001. Patients who were older than 18 and have 
been diagnosed with diabetes are included in the study. The study outcome was 
all cause mortality, where death records obtained from National Death Index 
were available through Dec. 31, 2006. Propensity score matching (PSM) was 
performed based upon patients’ smoking status. Time to event model was 
performed on the PS matched samples. RESULTS: There were 165,057 patients 
older than 18 participated NHIS survey between 1997 and 2001, of which, 10,194 
(6.18%) and had prior diabetes. Our estimation results suggest stop smoking for 
less than 5 years was associated with a 67% greater risk of death than having 
never smoked; stop smoking for more than 5 years did not have a different risk 
of mortality than those who never smoked. In addition, smoking 16-34 cigarettes 
per day was associated with 52% greater risk of death, and smoking more than 
34 cigarettes per day more than doubles the risk relative to the never smokers. 
CONCLUSIONS: This study indicates smoking reduced survival significantly for 
patients with diabetes; smoking cessation for more than 5 years prolonged 
survival. It provides important evidence to decision makers who attempt to 
advocate smoking cessation programs to patients with diabetes.  
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PRM73  
IDENTIFICATION OF PATIENTS AT HIGH RISK FOR SUBSEQUENT 
DEVELOPMENT OF ATRIAL FIBRILLATION OR STROKE USING A CLAIMS 
DATABASE  
Reynolds MR1, Hunter TD2, Mollenkopf SA3, Turakhia MP4 
1Harvard Clinical Research Institute, Boston, MA, USA, 2S2 Statistical Solutions, Inc., Cincinnati, 
OH, USA, 3Medtronic, Inc., Mounds View, MN, USA, 4Stanford University School of Medicine, 
Palo Alto, CA, USA  
OBJECTIVES: To evaluate the impact of epidemiologically established risk 
factors, both singular and multiple, on the rates of AF and stroke in a large 
claims database. METHODS: Using patients in the Truven Health MarketScan® 
Commercial and Medicare Supplemental Databases with enrollment during the 
entirety of 2007 (baseline), six conditions were considered as risk factors for 
stroke and AF: age (grouped as <65, 65-74, 75+), heart failure (HF), hypertension 
(HTN), diabetes, renal insufficiency, and coronary artery disease. A single 
categorical variable was created reflecting each patient’s exact combination of 
these conditions. Using this variable as the single predictor, Cox proportional 
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hazard models were then constructed for time to stroke and atrial fibrillation 
(AF) diagnoses through 2010. Hazard ratios (HR) were computed for each value of 
the predictor variable. RESULTS: Among patients with one risk factor, age 75+ 
was most strongly associated with the occurrence of both stroke and AF (HR 6.87 
and 9.16, respectively), followed by HF (HR 4.48 and 4.70). Hypertension (HR 2.06 
and 2.64) and diabetes (HR 2.03 and 1.82), along with age, were the risk factors 
with the highest prevalence. For patients age 75+, the additional presence of 
HTN or diabetes conferred nearly additive risk for stroke or AF (HR 9.64 and 14.83 
with HTN; 9.93 and 11.64 with diabetes). In contrast, the combination of age 75+ 
and HF on the risk of AF was supra-additive (HR 28.63). CONCLUSIONS: 
Previously established, common risk factors were found to be strongly associated 
with the subsequent occurrence of stroke and AF in a claims database. 
Additionally, the proposed methodology, combined with the large sample size of 
a claims database, provided valuable and easily interpretable insights on the 
levels of interactions among risk factors. Similar methodology may prove useful 
for establishing important risk combinations and interactions in the treatment 
and prevention of other conditions.  
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MODELING THE ECONOMIC IMPLICATIONS OF ALTERNATIVE TREATMENTS 
AND CARE LOCATIONS FOR ACUTE BACTERIAL SKIN AND SKIN STRUCTURE 
INFECTIONS: RESULTS FROM A DISCRETE EVENT SIMULATION  
Revankar N1, Ward A2, Kongnakorn T1, Pelligra C2, Fan W3, LaPensee KT3 
1United BioSource Corporation, London, UK, 2United BioSource Corporation, Lexington, MA, USA, 
3The Medicines Company, Parsippany, NJ, USA  
OBJECTIVES: To evaluate the potential economic implications of alternative 
treatment strategies for acute bacterial skin and skin structure infections 
(ABSSSIs) by capturing the impact of the initial empiric antibiotic selection, 
switches to 2nd line antibiotics, course length, route of administration and 
location of care. METHODS: The treatment pathway of each patient is simulated 
through various locations (emergency department (ED), inpatient, and 
outpatient). Patients responding at 72 hours may transfer to the outpatient 
setting to complete the course, switch antibiotic at discharge or receive 2nd line 
treatment due to lack of response or relapse. Analysis of US inpatient claims 
(Premier Hospital Database) provided length of stay information. Results from 
three scenarios are presented - each cohort was assigned to 1st line vancomycin 
(VAN). At discharge, one cohort completed the VAN course, one switched to oral 
linezolid (LIN) and the other to daptomycin (DAP). Costs (2012 USD from the 
Medicare perspective) and time in each location are accrued throughout the 
entire treatment course. RESULTS: Compared to VAN (10.1), hospital plus 
outpatient days were greater with LIN (13.4) and DAP (10.8), but total costs were 
reduced by $2,465 and $252 with LIN and DAP respectively, suggesting avoiding 
repeated outpatient infusion center visits lowers costs. Outpatient care 
comprises 32% (LIN) to 50% (VAN) of total costs and will remain important to 
consider as treatment pathways move further towards the outpatient setting. 
CONCLUSIONS: The choice of antibiotic and location of care have a substantial 
impact on resource use and costs. The economic implications of new treatment 
options currently in development such as long-acting lipoglycopeptide IV 
antibiotics (oritavancin and dalbavancin), which avoid repeated infusions and 
are anticipated to allow providers to shift more care to the ambulatory setting, 
can be assessed using the modeling framework presented here.  
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MODELLING DRUG CLASS EFFECTS IN BAYESIAN MULTIPLE TREATMENT 
COMPARISON META-ANALYSIS: APPLICATIONS IN EARLY AND ADVANCED 
PARKINSON'S DISEASE  
Thorlund K1, Kanters S2, O'Regan C3, Mills E1 
1Stanford University, Palo Alto, CA, USA, 2University of British Columbia, Vancouver, BC, 
Canada, 3Merck Sharp and Dohme Ltd, UK  
OBJECTIVES: To compared model fit and impact on key treatment effect 
estimates from incorporating the assumption of drug class effects in MTCs. 
METHODS: Two MTC data sets on early and advanced Parkinson’s disease (PD) 
comprising of several pharmacotherapies belonging to one of the three drug 
classes: dopamine receptor agonists (DOAs), monoamine-oxidase B inhibitors 
(MOAB-I), and adenosine A2 antagonists (A2A). We used three models: 1) a 
conventional random-effects MTC assuming all drugs were independent (model 
1); 2) an MTC assuming all drug belonging to the same class exhibited equal 
effects (model 2); and 3) an MTC assuming some overall drug class effect for each 
drug class, but allowing for each drug to differ from their class’ overall effect 
(model 3). We analysed the effect of the included interventions (and drug 
classes) on improvement on the Unified Parkinson’s Disease Rating Scale 
(UPDRS) part II and III. We compared model fits (DIC) and the impact on 
treatment effects and 95% credible intervals from using these three models. 
RESULTS: For the early PD data set, the model 3 yielded the smallest DIC. 
Treatment effects from all models were similar, but 95% credible intervals were 
generally narrower with model 3 and generally the widest with model 1. For the 
advanced PD data set, model 2 yielded a slightly smaller DIC than model 3, and 
both smaller DIC than model 1. However, all treatment effects and 95% credible 
intervals were highly similar. CONCLUSIONS: Incorporating the drug class effect 
assumption in MTCs may provider better model fits, and thus, more reliable 
estimates of comparative efficacy and safety.  
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STATED TIME-ALLOCATION, ADHERENCE, AND HEALTH-OUTCOME TRADEOFF 
PREFERENCES IN CYSTIC FIBROSIS HOUSEHOLDS  
Mohamed AF1, Johnson FR1, González JM1, Balp MM2 
1RTI Health Solutions, Research Triangle Park, NC, USA, 2Novartis Pharma AG, Basel, 
Switzerland  
OBJECTIVES: To quantify preferences for allocating hypothetical time savings in 
cystic fibrosis (CF) inhaled antibiotic treatment among health care and non-
health care activities. METHODS: Adult patients with a self-reported physician 
diagnosis of CF and parents of juvenile CF patients in the United States who have 
Pseudomonas aeruginosa in their culture at least twice a year completed a web-
enabled, discrete-choice experiment survey. Respondents evaluated treatment-
choice and routine-choice alternatives followed by stated adherence for 
themselves and other people. Questions required evaluating pairs of 
hypothetical inhalation devices and routine profiles defined by inhalation device 
features, side effects, time spent on inhaled antibiotic treatment, time spent on 
hypertonic saline, time spent on other CF-care activities, and lung function 
measured as forced expiratory volume in one second (FEV1). Respondents also 
answered a question indicating how they would allocate 80 hypothetical minutes 
of time savings per day among CF-care and non-CF-care activities (work, sleep, 
family activities, and social activities). Using a conceptual framework describing 
optimal time allocations within a health production function, random-
parameters logit models were used to quantify trade-off preferences among 
efficacy, treatment-time adherence, and competing time demands. RESULTS: 
The final sample included 174 adult patients and 130 parents. On average, adult 
patients would spend 9% of the time saved on additional CF-care activities and 
the remaining time would be almost evenly split between work, social activities, 
and sleep. Juvenile patients would spend 11% of the time saved on additional CF-
care activities and about 2.5 times more minutes in social activities than in work 
and 2 times more minutes in social activities than in sleep. CONCLUSIONS: 
Some of the time saved on taking inhaled antibiotics would be reallocated to 
activities with treatment benefits such as exercise and taking hypertonic saline 
as well as activities such as sleep that may improve health outcomes.  
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EXAMINING THE IMPACT OF EQ-5D AND LONG-STANDING HEALTH 
CONDITIONS ON SUBJECTIVE WELL-BEING  
Wu M1, Brazier J2 
1University of Sheffield, Sheffield, UK, 2University of Sheffield, Sheffield, South Yorkshire, UK  
OBJECTIVES: Generic preference-based measures like EQ-5D and SF-6D have 
been criticised for being narrowly focused on sub-set of health dimensions. One 
potential solution to this problem is to use the increasingly promoted subjective 
well-being approach, which considers the overall impact on a person’s well-
being and is based on experiences rather than hypothetical preferences. The aim 
of this study is to explore whether EQ-5D is adequate in reflecting the impact of 
long-standing health conditions on life satisfaction. METHODS: Using data from 
a UK general population cohort health (N = 13,591) collected between 2010 and 
2012 on EQ-5D, long-standing health conditions (self-reported), and life 
satisafaction using a response scale from 1 (completely dissatisfied) to 6 
(completely satisfied), this study employs ordered and generalised logit 
regression models. The impact of EQ-5D and long-standing health conditions on 
life satisfaction is assessed by examining the coefficients on dummy variables. 
RESULTS: The EQ-5D alone has coefficients that suggest anxiety/depression has 
the largest impact on life satisfaction (odds ratios ranging from 0.65 to 0.26). Self-
care has less impact (0.78) and pain/discomfort has the least (0.91). The long-
standing health conditions alone have coefficients that suggest insomnia has the 
largest impact on life satisfaction (0.71). The EQ-5D and long-standing health 
conditions have coefficients that suggest insomnia have a strong impact on life 
satisfaction (0.86) in the ordered logit model. Diabetes has a stronger impact on 
life satisfaction (0.72) in the generalised logit model. The largest difference in 
coefficients between the models is observed for severe anxiety/depression (odd 
ratio dropped significantly from 0.60 to 0.26). CONCLUSIONS: This study provides 
evidence of statistically significant differences between the models, and the 
comparison of the coefficients suggests inclusion of the bolt-on extra 
dimensions for EQ-5D could affect life satisfaction. Therefore, diabetes and 
insomnia could be newly discovered bolt-on dimensions for EQ-5D.  
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IMPACT OF MULTIPLE TREATMENT COMPARISON META-ANALYSIS ON VALUE 
OF INFORMATION EVALUATIONS: A CASE STUDY OF PHARMACOTHERAPIES 
FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASES  
Zafari Z1, Thorlund K2, FitzGerald M1, Lynd L1, Marra C1, Sadatsafavi M1 
1University of British Columbia, Vancouver, BC, Canada, 2McMaster University, Hamilton, ON, 
Canada  
OBJECTIVES: To compare the effect of using PTC or MTC on the results of cost-
effectiveness analysis of pharmacotherapies for chronic obstructive pulmonary 
disease (COPD). METHODS: A discrete-time Markov model was developed to 
reflect the cost and effectiveness of five COPD commonly used interventions 
including inhaled corticosteroids (ICS), long-acting beta agonists (LABA), 
ICS+LABA, long-acting muscarinic agents (LAMA), and no treatment (placebo). 
We pooled rate ratios (RR) of preventing COPD exacerbations using both Bayesian 
PTC and Bayesian MTC methods. We compared the impact of PTC versus MTC on 
the outcomes of the expected value of information (EVI) analysis. RESULTS: The 
expected value of perfect information (EVPI) values at willingness-to-pay of 
$50,000/QALY for all permutations of comparisons were calculated and 
compared between PTC and MTC analyses. The EVPI when all 5 treatments are 
compared is $1,281.1 for PTC and $557.3 for MTC analyses. When the future trial 
is planned to have only two intervention arms, among all ten possible 
permutations, the RCT that compares Placebo versus ICS+LABA had the highest 
EVPI when evidence was synthesized using MTC; on the other hand the RCT that 
compares LABA versus ICS+LABA had the highest EVPI using PTC analysis. 
Similarly, for RCTs with three and four arms, the strategy with highest EVPI 
changed across MTC and PTC analyses. CONCLUSIONS: The evidence generated 
using the entire network of comparisons resulted in substantial changes in the 
